(No subject)

[Guest guest]

MenAfriVac. A new HepA vaccine. It sounds like right now this is only in Africa, where arguably it might actually do some good.. Of course, how “crowded” is the "African schedule” getting? It’s probably worse there than here because I’m sure that they double up vaccines more (and triple, and quadruple, etc). Could this be the next vax added to the U.S. schedule? Or is there already a HepA vax here?

That raises an interesting question - peds make their money off of vaccine (sic) “well”-baby visits, and then when those kids get sick *because* of the vaccine-induced immune suppression and “resultant metabolic disruptions” Or “adverse reactions” - but they won’t call them that when the truth finally comes out and vaccine court is possibly overwhelmed by not just 15,000 autism cases, but *50,000* metabolic-disruption-adverse-event cases. They’ll play the “caused versus resulting in autism” shell game). But by that reasoning, peds would make *more* money if they adopted a semi-reasonable vaccination policy - still give 20 or so vaccines, but space them out. Of course, you have the schools and others screaming that “kids must be protected” - as soon as we possibly can stick the needles in them (not considering that perhaps the human immune system has a limit to how early it even can theoretically develop immunity - “Biology? Just hire Bill Gates to rewrite the damn immune system DNA!” End of species [this part is written in ancient Vulcan..]) But they couldn’t space it out too much, or parents wouldn’t be willing to bring the kids in 24 times instead of only 8 before they’re 2 years old.JimPublished online 9 November 2010 | Nature 468, 143 (2010) | doi:10.1038/468143aVaccine offers meningitis hopeFirst affordable and effective weapon against killer meningococcal meningitis A rolled out in Africa. Click for larger imageFrom Senegal to Ethiopia, December heralds the arrival of intense epidemics across Africa's 'meningitis belt' (see map). Killing thousands, and leaving many more with a host of after-effects such as brain damage and deafness, the scourge of meningitis A terrifies communities.This year will be different. Millions will receive a new vaccine, MenAfriVac, that promises protection against the meningococcal bacteriumNeisseria meningitidis. It is the culmination of ten years' work by an international consortium to develop a vaccine at a price low enough for massive use in Africa: just US$0.40 a dose. "MenAfriVac is a fantastic initiative," says Riordan, a meningitis expert at Alder Hey Children's NHS Foundation Trust, in Liverpool, UK. "For the first time, we may be able to prevent these huge epidemics."Vaccine offers meningitis hope : Nature News